Recruitment for SHORTEN-2 is officially complete! Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026! Hats off to this awesome research team! 🥳 #AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social

Fantastic - this will be an impactful study on treatment duration of blood stream Pseudomonas infection. Our centre already mostly does 7 days (and my prediction is that this will be non-inferior) but it's RCT like these that will shift dial across the board with persuasive evidence. #IDSky #AMR

Recruitment for SHORTEN-2 is officially complete! Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026! Hats off to this awesome research team! 🥳 #AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social

It’s encouraging to see new guidelines moving toward shorter and fully-oral treatments for BSIs. We are honoured to see some of our research cited to help shape these recommendations! 😃 #AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...

This metaanalysis of observational studies in SOT suggests that non-complicated graft infections could be treated 7d, and yet transplant patients have been excluded from most RCT on duration. Time for a #ShorterIsBetter RCT in #TxID! kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky

Check out this cool collaboration with @hernando-amado.bsky.social, just out in @natcomms.nature.com! We show that ciprofloxacin resistance rapidly declines in clinical P. aeruginosa strains under drug-free conditions, suggesting that ciprofloxacin restriction periods could help in clinics 🦠🧫

Variability in Durations of Therapy for Gram-Negative Bloodstream Infections and Factors Associated with Prolonged Durations ✅ Just Accepted ⭐ Editor's Choice #IDSky

Today we celebrated our 3rd Annual Researchers’ Meeting at the XXVIII Congress of @seimc.bsky.social! Only 2️⃣4️⃣ patients left to complete the trial! An amazing team doing an amazing work! 🤩🔝 #IDSky #AMSsky #TeamPride

Sociodemographic features have a strong influence on antibiotic use, and yet antimicrobial stewardship trials showed the lowest reporting rates of these data among RCTs in this systematic review. Fantastic work @seanong.bsky.social! An important heads-up for #AMSsky #IDsky researchers 💪🏼

Caring for patients with bronchiectasis poses a challenge for both pulmonologists and #AMSky teams. Standard 14d treatments for exacerbations lack good evidence support. This small RCT favors shorter durations such as 8d 👉🏻 publications.ersnet.org/content/erj/... #IDsky @bradspellberg.bsky.social

Fascinating and important study. May well be transformative in treatment of stubborn chronic lung infections such as by Pseudomonas aeruginosa in #cysticfibrosis and beyond rdcu.be/ekdWf

Calling all statisticians: we need your help. We'll soon be running an RCT comparing ceftazidime + iv fosfomycin to ceftaz alone in septic patients. Our hospital's stats unit is small & overworked. If you're available to freelance, we have a budget for this! #IDSky #Clinmicro #EpiSky #MedSky (1/2)

SOT patients have been systematically excluded from most RCTs on treatment duration, leading to prolonged courses still being the standard of care in many centers, even for non-complicated infections. (🧵1/3) #AMSky #IDsky #TxID

2025 Update of SPIRIT guidelines for RCT protocols: www.thelancet.com/action/showP... #IDSky #Medsky

To change or not to change? The necessity of replacing a catheter during a CAUTI remains a subject of ongoing debate. Please fill in this survey to help us assess potential global practice variation in catheter management! Completion only takes <2 minutes: forms.office.com/e/MRCMwUb2UK

6/ Además, hablamos de SHORTEN2, un estudio que dará mucho que hablar próximamente. 🔜📊 t.co/5whVazbnTo

🎙️💊 Sensible y Resistente - Episodio 1 @micromunidad.bsky.social ¿Hasta qué punto importa la duración del tratamiento antibiótico? 🧐 open.spotify.com/episode/4yak31… Hilo con claves y artículos 📚👇#AMSskyk#IDskyky

Systematic review of antibiotic durations in @jac-amr.bsky.social n=315 RCTs 85% demonstrated equivalence or non-inferiority of shorter therapy Only 7% in ICU, 14% in LMIC, and 15% low risk of bias academic.oup.com/jacamr/artic...

Haven't posted about SNAP for a while: But we've just hit 4000 participants. Almost at 3 years since opening. And submitting two late breaker oral abstracts to ESCMID Global. @escmid.bsky.social Amazing progress and more to come. @gurujosh.bsky.social @drtoddlee.bsky.social

Shorter is greener! 🍃♻️ Unnecessary antibiotics contribute to greenhouse gas emmissions. Want to know how much? 👉🏻 shorturl.at/52wOT Fantastic point! #IDSky #AMSsky

Paper looking at how Avycaz (ceftazidime-avibactam) can select for cross resistance to other beta-lactam/beta-lactamase inhibitor combinations. @aleciarokes.bsky.social @vscooper.micropopbio.org @dariavantyne.bsky.social Strong start to our P. aeruginosa research! journals.asm.org/doi/10.1128/...

In this table you can find a summary with different antimicrobials’ penetration into the bile (and the peritoneum). Hope you find it useful! 🙂 #AMSsky #IDOnc #IDSky

Are you a #Pseudomonas researcher? Please take our survey and help shape the direction and priority of future pseudomonas.com database development: forms.gle/gTPT6ruf3mqb... #microsky #idsky

Can we use Ciprofloxacin for treating Levofloxacin-R Pseudomonas and viceversa? 🤔 #AMSsky #PsWatch 👇🏻👇🏻

🔥The @escmid.bsky.social Study Group for Antimicrobial Stewardship (ESGAP) has joined BSky! We organize webinars, write newsletters, promote European research on AMS, participate in the AMS certificate and more Visit www.escmid.org/esgap/ to find more Also on www.linkedin.com/groups/90724...

#ShorterIsBetter in immunocompromised hosts? Short treatments are feasible in early responders without source control issues. A significant number of observational studies serve as proof-of-concept on the feasibility of short courses in selected patients (see ⚠️) #AMSsky #IDOnc #TxID #IDsky

Excited to share our work on broadly effective phage-antibiotic cocktails. We report 4 cocktails that each work against 96% of 153 antibiotic resistant Pseudomonas isolates. Check it out here: www.nature.com/articles/s41... Congrats to Kevin Kim @KevinMinyo6651

Only 58 patients to go! Recruitment is moving along as planned, and fingers crossed, we’ll be done before summer. Huge shoutout to the @shorten2trial.bsky.social team for keeping up the great work! #AMSsky #IDSky #ShorterIsBetter

Not always Pseudomonas… #AMSky #IDSky

Despite our growing antibiotic arsenal, non-fermenting GNB frequently keep leaving us without therapeutic options. This article explores the present and the future of therapies against DTR NF-GNB: journals.lww.com/co-infectiou... #PsWatch #AMSsky #IDsky

#PCCMSky Update Up to 95 members Repost so those new to this place can populate their following list with good PCCM people Reply if you are not on this list and should be go.bsky.app/88wg6oG

Reposting a 2023 note: Calc NNT w meta-analysis. Thanks to @wwrighid.bsky.social for using highest weight ctrl event prop, @drtoddlee.bsky.social for suggesting pooling single prop from ctrl grp, and @matthewbjane.bsky.social meta-analysis guru for correct equation to calc event prop. #idsky

What's the best duration for treating uncomplicated P. aeruginosa-BSI? This metaanalysis of observational studies (n=1746) found no differences in recurrence+mortality for short (<10d) compared to prolonged treatments. 📖 www.journalofhospitalinfection.com/article/S019... #PsWatch #AMSsky #IDsky

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and emerging treatment. DOI: 10.1080/1040841X.2024.2429599 https://pubmed.ncbi.nlm.nih.gov/39556143/

New β-lactams allow treating Pseudomonas that were untreatable, but… are they better than previous options? This meta-analysis of RCTs shows they are not superior to prior alternatives when available: www.ajicjournal.org/article/S019... 👐🏻 Use them wisely, make them last #PsWatch #AMSsky #IDsky

Struggling to keep up with the new (and upcoming) antibiotics for Gram-negatives? A quick reference guide! #AMSsky #IDSky

Next at @bsacandjac.bsky.social AMR workshop: @rwheatley8.bsky.social showing that spontaneous antibiotic resistance mutations in P. aeruginosa affect ability to invade cultures of respiratory bugs. Saw increase/decrease, depending on mutation & competitor. academic.oup.com/evlett/artic... #MicroSky

Recent Systematic Review & Meta,May 2024 6 retros N:1746 Short Vs.Prolonged Duration of Therapy for Pseudomonas aeruginosa Bacteremia No sig # in 30d mortality Ongoing RCTs: SHORTEN-2👇 OPTIMISE Just released:BALANCE 7d NI 14d[~5%PSA] #idsky #medsky www.journalofhospitalinfection.com/article/S019...

Interested in learning about Pseudomonas aeruginosa? We’ve created a dedicated feed where you will find from clinical trials to diagnostics or cutting-edge research: bsky.app/profile/did:... Tag your posts with #PsWatch to join the conversation! #IDSky #MicroSky #AMR #AMSsky #IDOnc #TxID

We lack oral options for most MDR-GNB among current or upcoming antibiotics, so ambulatory care for these patients will relay largely on #OPAT. The good news: most new agents are stable to be administered via infusion bags or elastomeric pumps 👉 www.mdpi.com/1999-4923/15... #AMSsky #IDsky

Our @shorten2trial.bsky.social aims to confirm that 7-day treatments are superior to 14-day courses for uncomplicated P. aeruginosa BSI. Check out our full protocol 👉🏻 journals.plos.org/plosone/arti... #AMSsky #IDSky

~ 5 % (170/ 3608 ) Pseudomonas spp , sub group analysis? Now we have more data about Pseudomonas bactremia, awaiting for the definitive answer from SHORTEN-2 RCT SHORTEN-2 : RCT 7 vs 14 days of treatment for P. aeruginosa BSI. #idsky